Innovative AI technology helps personalized ca

Tokyo, Salt Lake City, Indianapolis – Hitachi, Ltd. (TSE: 6501, Hitachi), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve the care of patients with type 2 diabetes mellitus requiring complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood sugar and avoid serious complications, such as vision loss and kidney disease.

For this small group of patients, physicians may have limited clinical decision-making experience or evidence-based advice for choosing drug combinations. The solution is to increase the number of patients to support the development of general principles to guide decision-making. However, combining patient data from multiple healthcare institutions requires deep expertise in artificial intelligence (AI) and extensive experience in developing machine learning models using sensitive and complex healthcare data.

Researchers from Hitachi, U of U Health, and Regenstrief teamed up to develop and test a new AI method that analyzed data from electronic health records in Utah and Indiana and learned from generalizable treatment regimens of patients with type 2 diabetes with similar characteristics. These models can now be used to help determine an optimal drug regimen for a specific patient.

Some of the results of this study are published in the peer-reviewed medical journal, Journal of Biomedical Informaticsin the article, “Predicting pharmacotherapeutic outcomes for type 2 diabetes: an evaluation of three approaches to leveraging electronic health record data from multiple sources”.

Hitachi had been working with U of U Health for several years on the development of a drug therapy selection system for the treatment of diabetes[1]. However, the system was not always able to accurately predict more complex and less prevalent treatment patterns because it did not have enough data. In addition, it was not easy to use data from multiple facilities, as it was necessary to account for differences in patient disease states and therapeutic medications prescribed between facilities and regions. To address these challenges, the project partnered with Regenstrief to enrich the data it was working with.

The new AI method initially groups patients with similar disease states and then analyzes their treatment regimens and clinical outcomes. It then associates the patient of interest with disease state clusters and predicts the range of potential outcomes for the patient based on various treatment options. Researchers evaluated the method’s effectiveness in predicting positive outcomes given treatment regimens given to patients with diabetes in Utah and Indiana. The algorithm was able to support drug selection for more than 83% of patients, even when two or more drugs were used together.

In the future, the research team plans to help diabetic patients who require complex treatment to test the effectiveness of various drug combinations and then, together with their doctors, decide on a treatment plan that is right for them. . This will lead not only to better diabetes management, but also to increased patient engagement, compliance and quality of life.

The three parties will continue to evaluate and improve the effectiveness of the new AI method and contribute to future patient care through new health informatics research.

Hitachi will accelerate its efforts, including the practical application of this technology through collaboration between its healthcare and IT business divisions and its R&D group. GlobalLogic Inc., a Hitachi Group company and leader in digital engineering, promotes healthcare-related projects in the United States, will also deepen collaboration in this area. Through these efforts, the entire Hitachi Group will contribute to the health and safety of people.

Go to to see an image of the AI ​​grouping patients and analyzing treatment regimens and effectiveness

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a better quality of life by driving innovation through data and technology as a social innovation enterprise . Hitachi is focused on strengthening its contribution to the environment, the resilience of business and social infrastructure as well as comprehensive programs to improve safety and security. Hitachi solves problems faced by customers and society in six areas: IT, energy, mobility, industry, smart life and automotive systems with its proprietary Lumada solutions. The company’s consolidated revenue for fiscal 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information about Hitachi, please visit the company’s website at

About University of Utah Health

The University of Utah Health provides cutting-edge, compassionate medicine for a referral area that encompasses 10% of the United States, including Idaho, Wyoming, Montana, and much of Nevada. The hub of health science research and education in the region, U of U Health has a $428 million research enterprise and trains the majority of Utah’s physicians, including more than 1,250 providers. of health care every year in its schools of medicine and dentistry and colleges of nursing. , Pharmacy and Health. With more than 20,000 employees, the system includes 12 community clinics and four hospitals. For ten consecutive years, U of U Health has ranked among the top 10 US academic medical centers in the Vizient Quality and Accountability study.
About the Regenstrief Institute

Founded in 1969 in Indianapolis, the is a local, national and global leader dedicated to a world where better information enables people to end disease and achieve true health. A key research partner of Indiana University, Regenstrief and its researchers are responsible for a growing number of major healthcare innovations and studies. Examples range from developing global health information technology standards that enable the use and interoperability of electronic health records, to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the world.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible to everyone. His vision continues to guide the institute’s research mission.

[1]Hitachi, Ltd. Press Release, March 12, 2018 “Drug Therapy Screening System Supports Clinician-Patient Shared Decision-Making in Diabetes Treatment”

Press release from Hitachi, Ltd., February 27, 2019 “New clinical study tests drug therapy selection system that aims to improve the impact of diabetes treatment”

Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Previous China's 'mind-blowing' claims - New AI system can design hypersonic weapons on its own without human intervention
Next Indian telecom companies threaten to shut down internet services in Nepal over payment